Juvederm More Effective at Treating Perioral Lines, Says Study 

Juvederm More Effective at Treating Perioral Lines, Says Study 

According to research presented at a session during the American Academy of Dermatology Annual Meeting, Juvederm showed a response rate that was not only higher, but also showed more improvement in the treatment of moderate-to-severe perioral lines when compared with Belotero.  

A research team that consisted of Kimberly Butterwick, MD and colleagues conducted a six month, double-blind and controlled multicenter study that compared Juvederm Ultra (24 mg/mL hyaluronic acid, 0.3% lidocaine; HYC-24L, Allergan) with Belotero Balance (22.5 mg/ml hyaluronic acid; CPM-22.5, Merz Aesthetics) as treatment for 136 adults who had perioral lines that were moderate-to-severe. Out of those who started, 131 people completed the study.  

Butterwick noted that the products used were not diluted and came straight from the bottle. Before and after the treatment, pain was measured, and after the treatment Tyndall effect and bruising were measured.  

Used as the main endpoint of the study was a validated four point Perioral Lines Severity Scale at six months. Participants who had a one point improvement were considered responders. The total volume injected was 1.32cc for those who received CPM-22 and 1.18cc for those who received HYC-24L.  

Seventy-two percent of patients in the CPM-22.5 (Belotero) treatment group reached endpoint compared with 87 percent of those in the HYC-24L (Juvederm Ultra). So, an improvement that was significantly greater in perioral lines was reported by those treated with Juvederm compared with the patients treated with Belotero at all points, with the greatest difference between the two reported at six months, said the researchers. One Tyndall effect was reported in the CPM-22.5 group.  

“Both products had a similar look, a natural feel and ease of injection, but HYC-24L provided more effective correction with less pain than CPM-22.5,” Butterwick said. “HYC’s greater persistence of effectiveness at month 6 suggests that it may exhibit a longer duration of benefit than CPM.” 

 

 

 



Leave a Reply

Your email address will not be published. Required fields are marked *


%d bloggers like this: